Akari Therapeutics (AKTX) to Release Earnings on Thursday

Akari Therapeutics (NASDAQ:AKTX) is projected to post its Q2 2025 results before the market opens on Thursday, September 25th. Analysts expect Akari Therapeutics to post earnings of ($0.09) per share for the quarter. Individuals can check the company’s upcoming Q2 2025 earningsummary page for the latest details on the call scheduled for Wednesday, August 13, 2025 at 4:00 PM ET.

Akari Therapeutics Trading Up 5.1%

NASDAQ:AKTX opened at $0.79 on Thursday. Akari Therapeutics has a 12 month low of $0.57 and a 12 month high of $3.85. The stock has a 50 day moving average of $0.95 and a two-hundred day moving average of $1.13.

Wall Street Analyst Weigh In

A number of research firms recently commented on AKTX. Wall Street Zen began coverage on Akari Therapeutics in a report on Wednesday, May 21st. They issued a “sell” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $1.60 price objective on shares of Akari Therapeutics in a report on Tuesday, September 9th. Finally, Maxim Group began coverage on Akari Therapeutics in a report on Friday, July 18th. They issued a “buy” rating and a $5.00 price objective on the stock. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $3.30.

About Akari Therapeutics

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.